Unidad de Gestión Clínica de Endocrinología y Nutrición del Hospital Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain.
Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain.
Microbiol Spectr. 2021 Dec 22;9(3):e0053521. doi: 10.1128/Spectrum.00535-21. Epub 2021 Nov 17.
Little is known about the influence of gastric microbiota on host metabolism, even though the stomach plays an important role in the production of hormones involved in body weight regulation and glucose homeostasis. Proton pump inhibitors (PPIs) and Helicobacter pylori alter gut microbiota, but their impact on gastric microbiota in patients with obesity and the influence of these factors on the metabolic response to bariatric surgery is not fully understood. Forty-one subjects with morbid obesity who underwent sleeve gastrectomy were included in this study. The H. pylori group was established by the detection of H. pylori using a sequencing-based method ( = 16). Individuals in whom H. pylori was not detected were classified according to PPI treatment. Gastric biopsy specimens were obtained during surgery and were analyzed by a high-throughput-sequencing method. Patients were evaluated at baseline and 3, 6, and 12 months after surgery. β-Diversity measures were able to cluster patients according to their gastric mucosa-associated microbiota composition. H. pylori and PPI treatment are presented as two important factors for gastric mucosa-associated microbiota. H. pylori reduced diversity, while PPIs altered β-diversity. Both factors induced changes in the gastric mucosa-associated microbiota composition and its predicted functions. PPI users showed lower percentages of change in the body mass index (BMI) in the short term after surgery, while the H. pylori group showed higher glucose levels and lower percentages of reduction in body weight/BMI 1 year after surgery. PPIs and H. pylori colonization could modify the gastric mucosa-associated microbiota, altering its diversity, composition, and predicted functionality. These factors may have a role in the metabolic evolution of patients undergoing bariatric surgery. The gut microbiota has been shown to have an impact on host metabolism. In the stomach, factors like proton pump inhibitor treatment and Helicobacter pylori haven been suggested to alter gut microbiota; however, the influence of these factors on the metabolic response to bariatric surgery has not been fully studied. In this study, we highlight the impact of these factors on the gastric microbiota composition. Moreover, proton pump inhibitor treatment and the presence of Helicobacter pylori could have an influence on bariatric surgery outcomes, mainly on body weight loss and glucose homeostasis. Deciphering the relationship between gastric hormones and gastric microbiota and their contributions to bariatric surgery outcomes paves the way to develop gut manipulation strategies to improve the metabolic success of bariatric surgery.
尽管胃在调节体重和葡萄糖稳态相关激素的产生方面发挥着重要作用,但人们对胃微生物群如何影响宿主代谢知之甚少。质子泵抑制剂(PPIs)和幽门螺杆菌会改变肠道微生物群,但它们对肥胖患者胃微生物群的影响以及这些因素对减肥手术代谢反应的影响尚未完全阐明。本研究纳入了 41 例接受袖状胃切除术的病态肥胖患者。通过基于测序的方法( = 16)检测幽门螺杆菌建立了幽门螺杆菌组。根据是否检测到幽门螺杆菌将未检测到幽门螺杆菌的个体分类。在手术期间获取胃活检标本,并通过高通量测序方法进行分析。患者在基线和术后 3、6 和 12 个月进行评估。β多样性测量能够根据胃黏膜相关微生物群落组成对患者进行聚类。幽门螺杆菌和 PPI 治疗是胃黏膜相关微生物群落的两个重要因素。幽门螺杆菌降低了多样性,而 PPI 改变了 β 多样性。这两个因素都引起了胃黏膜相关微生物群落组成及其预测功能的变化。PPI 使用者在手术后短期内 BMI 的变化百分比较低,而幽门螺杆菌组在手术后 1 年时血糖水平较高,体重/ BMI 的降低百分比较低。PPIs 和幽门螺杆菌定植可能会改变胃黏膜相关微生物群,改变其多样性、组成和预测功能。这些因素可能在接受减肥手术的患者的代谢演变中发挥作用。肠道微生物群已被证明对宿主代谢有影响。在胃中,质子泵抑制剂治疗和幽门螺杆菌等因素被认为会改变肠道微生物群;然而,这些因素对减肥手术代谢反应的影响尚未得到充分研究。在这项研究中,我们强调了这些因素对胃微生物群组成的影响。此外,质子泵抑制剂治疗和幽门螺杆菌的存在可能会对减肥手术结果产生影响,主要是对体重减轻和葡萄糖稳态的影响。阐明胃激素与胃微生物群之间的关系及其对减肥手术结果的贡献,为开发肠道操作策略以提高减肥手术的代谢成功率铺平了道路。